PRIMARY MYELOFIBROSIS
Clinical trials for PRIMARY MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for PRIMARY MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Drug combo shows promise against rare bone marrow cancers
Disease control CompletedThis study tested a combination of two drugs, ruxolitinib and azacytidine, in 121 people with myelofibrosis or related blood cancers. The goal was to see if the combo could shrink tumors or improve blood counts. While the treatment aims to control the disease, it is not a cure, a…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 10:35 UTC
-
New Two-Step transplant shows promise for blood cancer patients
Disease control CompletedThis study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. The approach uses low-dose chemo and radiation before a donor stem cell infusion, followed by drugs to prevent graft-versus-host disease. The goal was to control the cancer…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated May 26, 2026 10:30 UTC
-
New drug combo may reduce deadly transplant complication in blood cancer patients
Disease control CompletedThis study tested whether adding the drug itacitinib to the usual two-drug regimen (tacrolimus and sirolimus) could better prevent graft-versus-host disease (GVHD) in 59 adults with blood cancers (acute leukemia, myelodysplastic syndrome, or myelofibrosis) undergoing a donor stem…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New combo therapy shows promise for rare bone marrow cancer
Disease control CompletedThis study looked at whether giving a JAK inhibitor drug before a donor stem cell transplant helps people with myelofibrosis, a serious bone marrow disorder. The treatment aims to reduce symptoms like an enlarged spleen and inflammation, and improve survival after transplant. 61 …
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New combo therapy offers hope for myelofibrosis patients who failed standard care
Disease control CompletedThis study tested a combination of two drugs, fedratinib and nivolumab, in 30 adults with myelofibrosis whose disease did not respond well to standard JAK-inhibitor therapy. The goal was to see if the combo could shrink the spleen, improve symptoms, or reduce the need for blood t…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
Bomedemstat shows promise for Long-Term control of rare blood cancers
Disease control CompletedThis study looked at the long-term safety and effectiveness of the drug bomedemstat in 81 people with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Participants had already taken bomedemstat in an earlier study and continued treatment to see how well it cont…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) • Aim: Disease control
Last updated May 18, 2026 12:07 UTC
-
New drug combo shows promise for rare blood cancers
Disease control CompletedThis study tested a new pill called pelabresib in people with certain blood cancers, including myelofibrosis and leukemia. The goal was to see if it could shrink enlarged spleens and reduce the need for blood transfusions. The drug was given alone or with another medicine (ruxoli…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE1, PHASE2 • Sponsor: Constellation Pharmaceuticals • Aim: Disease control
Last updated May 08, 2026 12:01 UTC